Mexiletine

## What is Mexiletine?

Mexiletine is a prescription oral medication belonging to the Class IB category of antiarrhythmic drugs — a subgroup that also includes lidocaine and tocainide. Marketed under the brand name Mexitil in the United States and as Namuscla in Europe (for the myotonia indication), mexiletine has been available since the late 1970s and remains a valuable tool in the management of certain ventricular arrhythmias, neuropathic pain syndromes, and skeletal muscle channelopathies.

The drug was developed as an orally bioavailable analogue of lidocaine, which — despite its excellent antiarrhythmic efficacy — cannot be given orally because of near-complete first-pass hepatic metabolism. By modifying the chemical structure, pharmaceutical researchers produced mexiletine, a compound with roughly 90% oral bioavailability, predictable pharmacokinetics, and a manageable side-effect profile. Its primary approved indication in the United States is the suppression of symptomatic ventricular arrhythmias, including documented ventricular tachycardia judged to be life-threatening.

Chemically, mexiletine is a phenylethylamine derivative with a molecular formula of C11H17NO and a molecular weight of approximately 179 g/mol. Its structure resembles that of lidocaine in the aromatic and amine regions, but its modified ether linkage and absence of the amide bond that makes lidocaine susceptible to first-pass metabolism account for its excellent oral activity. The hydrochloride salt form is used in commercial preparations, which improves stability and dissolution properties.

Over the decades, the clinical community has recognized several important off-label applications for mexiletine. Neurologists and pain specialists use it to reduce the burning, shooting, or electric-shock pain characteristic of peripheral neuropathies — particularly painful diabetic neuropathy. Neuromuscular specialists rely on it as a cornerstone treatment for non-dystrophic myotonias such as myotonia congenita (Thomsen and Becker disease) and paramyotonia congenita, where it reliably reduces the muscle stiffness and weakness that severely impair patients' quality of life. In Europe, the European Medicines Agency approved mexiletine (Namuscla) specifically for non-dystrophic myotonia in adults in 2018, making it the first approved pharmacotherapy for this group of rare diseases.

Mexiletine was first synthesized in the 1970s by Boehringer Ingelheim and initially developed as an anticonvulsant before its antiarrhythmic properties were recognized. The drug received FDA approval in 1985 for ventricular arrhythmias. Since the patents expired, multiple generic versions have become available in the United States, making it relatively affordable compared to many specialty cardiac medications.

Understanding mexiletine — how it works, when it is appropriate, what risks it carries, and how it interacts with other medications — is essential for patients and clinicians who use it.

## How Does Mexiletine Work?

Mexiletine exerts its therapeutic effects by blocking fast voltage-gated sodium channels, specifically the Nav channels responsible for the rapid depolarization phase (phase 0) of the cardiac and skeletal muscle action potential. This mechanism places it squarely in the same mechanistic family as lidocaine, procainamide (with important differences), and the membrane-stabilizing local anesthetics.

At the molecular level, mexiletine binds preferentially to sodium channels in their inactivated state — the conformation channels adopt immediately after they open and depolarize the cell, before they can reset to the resting (closed) state. By stabilizing the inactivated conformation, mexiletine slows the rate at which channels recover and become available to open again. This reduces the maximum rate of rise of the action potential upstroke (Vmax), thereby slowing conduction velocity in rapidly firing abnormal foci while having comparatively little effect on tissues firing at normal sinus rates.

This property is described as use-dependence or frequency-dependence: the faster a tissue fires, the more channels are in the inactivated state at any given moment, and therefore the more channels mexiletine can block. Abnormal ectopic foci in the ventricle that fire at rapid, irregular rates accumulate disproportionately more block than the normally paced myocardium — an elegant pharmacological selectivity.

A key feature that distinguishes Class IB agents from their Class IA counterparts (such as quinidine and procainamide) is a rapid rate of dissociation from the sodium channel. Mexiletine binds and unbinds quickly, which means it does not significantly accumulate in channels during normal sinus rhythm and does not substantially prolong the cardiac action potential duration or the QT interval. This is why mexiletine is generally considered lower risk for the torsades de pointes arrhythmia that is a well-recognized hazard of Class IA and Class III agents.

In skeletal muscle, mexiletine targets Nav1.4 channels. Myotonia congenita is caused by loss-of-function mutations in the CLCN1 gene (encoding chloride channels) or gain-of-function mutations in SCN4A (encoding Nav1.4), both of which result in prolonged membrane depolarization and repetitive, involuntary muscle firing — experienced clinically as stiffness and difficulty relaxing grip after contraction. By reducing the availability of Nav1.4 channels, mexiletine curtails this abnormal repetitive firing and restores more normal muscle relaxation.

In peripheral nerves, mexiletine inhibits Nav1.7 and Nav1.8 channels expressed in nociceptive (pain-sensing) neurons. In conditions like diabetic neuropathy, injured or demyelinated nerve fibers develop abnormal spontaneous discharges mediated by these channels. Mexiletine dampens this ectopic neural firing, reducing the continuous pain signals sent to the brain.

## What Is Mexiletine Used For?

Mexiletine's pharmacological profile — sodium channel blockade in both cardiac and neural/skeletal muscle tissue — gives it a range of clinical applications.

Ventricular Arrhythmias

The FDA-approved indication for mexiletine is the treatment of documented, symptomatic ventricular arrhythmias that are judged to be life-threatening, particularly sustained ventricular tachycardia. It may also be used for frequent, symptomatic premature ventricular contractions (PVCs) when other measures have failed or are contraindicated.

An important historical context is the Cardiac Arrhythmia Suppression Trial (CAST), published in 1989, which demonstrated that certain Class IC antiarrhythmics (flecainide and encainide) increased mortality when given to post-myocardial infarction patients with asymptomatic ventricular arrhythmias despite effectively suppressing the arrhythmias on Holter monitoring. Although mexiletine is a Class IB — not Class IC — agent, this landmark finding fundamentally changed how all antiarrhythmics are used: the goal shifted from suppressing arrhythmias on a monitor to improving symptoms and outcomes. Current guidelines therefore restrict mexiletine (and other Class I agents) to patients with symptomatic, life-threatening ventricular arrhythmias and recommend against routine use in asymptomatic post-MI patients.

Mexiletine is sometimes combined with amiodarone in patients with refractory ventricular tachycardia who have implantable cardioverter-defibrillators (ICDs), when ICD shocks remain frequent despite amiodarone monotherapy. The combination can reduce the arrhythmia burden without requiring very high doses of either drug.

Non-Dystrophic Myotonia

Myotonia congenita (both the dominant Thomsen form and the recessive Becker form) and paramyotonia congenita are characterized by muscle stiffness that worsens with cold, exercise, or prolonged rest. Before mexiletine, treatment options were limited largely to quinine, tocainide (withdrawn from the market due to toxicity), or mexiletine used off-label. Multiple clinical trials, including the CINCH (Controlled Investigation of Novel Channelopathy Treatments) trials and confirmatory European studies, demonstrated that mexiletine significantly reduced myotonia stiffness scores, improved grip relaxation time, and enhanced functional measures such as walking speed in patients with non-dystrophic myotonia. These data formed the basis for the European approval of Namuscla (mexiletine 200 mg capsules) specifically for this indication.

In clinical practice, mexiletine typically produces dramatic improvement in most myotonia patients, often within days of starting therapy. Many patients describe being able to open a jar, walk normally in cold weather, or drive a car for the first time after starting mexiletine — outcomes that underscore the profound functional impact of this treatment.

Neuropathic Pain

Off-label use of mexiletine for neuropathic pain — most extensively studied in painful diabetic peripheral neuropathy — is supported by multiple randomized, placebo-controlled trials. A 2018 Cochrane systematic review identified mexiletine as providing modest but statistically significant pain relief versus placebo in diabetic neuropathy, with a number needed to treat (NNT) roughly comparable to other first-line neuropathic pain agents. Mexiletine is generally considered a second- or third-line option for neuropathic pain given that its side-effect profile (particularly GI effects and CNS effects) and the need for cardiac monitoring make it less convenient than first-line agents such as gabapentin, duloxetine, or pregabalin.

Other Off-Label Uses

Emerging evidence supports mexiletine in other conditions. In Long QT Syndrome type 3 (LQT3) — caused by gain-of-function mutations in SCN5A that produce a persistent late sodium current — mexiletine can reduce QTc interval and suppress arrhythmia risk. Case series and small trials also report benefit in erythromelalgia (a rare condition causing episodic burning pain and redness in the extremities due to Nav1.7 mutations) and in certain forms of channelopathy-related periodic paralysis.

## Dosing and Administration

Mexiletine should always be initiated under medical supervision, preferably in a monitored setting for patients with serious ventricular arrhythmias.

For Ventricular Arrhythmias

The usual adult starting dose is 200 mg every 8 hours (three times daily) taken with food or antacids to reduce GI adverse effects. After 2–3 days, the dose may be adjusted based on efficacy and tolerability. The usual maintenance dose ranges from 200–300 mg every 8 hours. Some patients may be controlled with twice-daily dosing (400–450 mg every 12 hours), though three-times-daily dosing is more typical. The maximum recommended daily dose is 1200 mg/day. When switching from intravenous lidocaine to oral mexiletine, the first mexiletine dose is usually given 3–6 hours after the lidocaine infusion is stopped.

For Non-Dystrophic Myotonia (EU-approved regimen)

The Namuscla prescribing information specifies an initial dose of 167 mg (Namuscla formulation) once daily for 7 days, increasing to 333 mg once daily as maintenance. Dose adjustments are guided by clinical response and tolerability. Doses above 500 mg/day have not been studied in this population.

For Neuropathic Pain (off-label)

Typical dosing studied in clinical trials ranges from 450–750 mg/day in three divided doses. Start low (150–200 mg once daily) and titrate slowly to minimize side effects.

Special Populations

Hepatic impairment: Because mexiletine is extensively metabolized in the liver, dose reduction and more frequent monitoring are warranted in patients with significant hepatic dysfunction. Renal impairment: No dose adjustment is required for mild-to-moderate renal impairment, but caution is needed in severe renal failure. Elderly patients: Use lower starting doses due to age-related reductions in hepatic blood flow and potential for increased sensitivity to CNS effects. Smokers: Cigarette smoking induces CYP1A2 and increases mexiletine clearance by approximately 40%, potentially requiring higher doses; conversely, smoking cessation during therapy may cause mexiletine levels to rise, sometimes precipitating toxicity.

## Side Effects

Mexiletine has a well-characterized side-effect profile. The majority of adverse effects are dose-related and involve the gastrointestinal (GI) tract or central nervous system (CNS).

Gastrointestinal Effects

Nausea, vomiting, heartburn, and dyspepsia are the most common reasons patients discontinue mexiletine, affecting 30–40% of patients in clinical trials. These effects are substantially reduced by taking the drug with food, milk, or antacids. Abdominal pain, diarrhea, or constipation occur less frequently. The GI side effects tend to be most prominent when therapy begins and often improve over the first few weeks as the patient adjusts.

Central Nervous System Effects

CNS adverse effects are the second major category and include dizziness, lightheadedness, tremor, coordination difficulties (ataxia), blurred vision, diplopia, tinnitus, nervousness, sleep disturbances, and headache. These are generally dose-dependent: they become more prominent at higher plasma levels (above 2.0 mcg/mL) and may signal impending toxicity. At toxic concentrations, mexiletine can cause confusion, dysarthria, frank ataxia, and seizures.

Cardiovascular Effects

Proarrhythmia — the paradoxical worsening of existing arrhythmias or creation of new ones — is the most dangerous cardiovascular adverse effect. Mexiletine can slow conduction through diseased tissue and create new reentrant circuits in patients with structural heart disease, particularly those with prior myocardial infarction and significantly impaired left ventricular function. Hypotension may occur, particularly in patients with already compromised cardiac function. Bradycardia, worsening of AV block, and sinus node dysfunction are less common but possible.

Hepatic Effects

Rare but clinically significant cases of hepatotoxicity have been reported, including elevated liver enzymes and hepatic necrosis. Most cases resolved after drug discontinuation. Liver function tests should be checked if a patient develops jaundice, abdominal pain, or unexplained fatigue during treatment.

Hematologic Effects

Leukopenia and agranulocytosis are rare but documented complications. Patients who develop fever, chills, sore throat, or unusual bleeding during mexiletine therapy should have a complete blood count checked promptly.

Dermatological and Other Effects

Skin rash occurs in a minority of patients and is usually mild. Rare cases of a positive antinuclear antibody (ANA) test have been reported, analogous to the drug-induced lupus seen with some other antiarrhythmics, though clinical lupus is very uncommon with mexiletine. Mild elevations in liver enzymes without symptoms are occasionally seen on routine laboratory testing and may resolve spontaneously.

Managing Side Effects

Most GI and CNS side effects can be managed by taking the drug with food, using the lowest effective dose, and titrating slowly. If tremor is troublesome, a modest dose reduction often provides relief without sacrificing efficacy. Persistent or worsening CNS symptoms should prompt plasma level measurement and a reduction in dose. Patients should be reassured that GI effects typically diminish over the first few weeks of therapy as tolerance develops, and that abrupt discontinuation of mexiletine for arrhythmia indications should be avoided without medical guidance, as rebound arrhythmias are theoretically possible.

## Drug Interactions

Mexiletine is subject to several clinically important drug interactions, primarily because it is metabolized by CYP1A2 (major) and CYP2D6 (minor), and it inhibits CYP1A2 itself, affecting the metabolism of other CYP1A2 substrates.

Pharmacokinetic Interactions (drugs affecting mexiletine levels)

Fluvoxamine, a strong CYP1A2 inhibitor used as an antidepressant and for OCD, can markedly increase mexiletine plasma concentrations — sometimes more than doubling exposure. This combination should be approached with extreme caution, with dose reduction of mexiletine and close clinical and level monitoring if combination is unavoidable. Ciprofloxacin, a commonly used fluoroquinolone antibiotic and moderate CYP1A2 inhibitor, can meaningfully raise mexiletine levels; short courses of ciprofloxacin during mexiletine therapy warrant heightened vigilance for toxicity. Rifampin is a potent inducer of CYP1A2 and CYP3A4; co-administration can reduce mexiletine AUC by 50% or more, potentially leading to loss of arrhythmia control. Phenytoin and phenobarbital similarly induce hepatic enzymes and reduce mexiletine levels. Omeprazole, through CYP1A2 inhibition, may modestly elevate mexiletine concentrations. Smoking (tobacco) powerfully induces CYP1A2, and smokers require approximately 40% more mexiletine to achieve equivalent plasma levels; quitting smoking during therapy necessitates close monitoring for rising levels.

Pharmacokinetic Interactions (mexiletine affecting other drug levels)

Mexiletine inhibits CYP1A2 at therapeutic concentrations. Theophylline, a CYP1A2 substrate with a narrow therapeutic index used in asthma and COPD, can reach toxic levels when mexiletine is added; theophylline levels should be monitored and the dose reduced. Caffeine clearance is also reduced by mexiletine, leading to higher caffeine levels — clinically modest but relevant in sensitive individuals. Metoprolol, a CYP2D6 substrate, may have slightly increased exposure when combined with mexiletine, though the CYP2D6 inhibitory contribution of mexiletine is less potent than its CYP1A2 inhibition.

Pharmacodynamic Interactions

Co-administration with other antiarrhythmics (amiodarone, flecainide, sotalol, dronedarone) carries risks of additive proarrhythmia, excessive conduction slowing, or QT prolongation, even though mexiletine itself does not prolong QT. When combination antiarrhythmic therapy is necessary, it should be managed by an electrophysiologist with careful ECG monitoring. Antacids, particularly magnesium-aluminum hydroxide, may slow mexiletine absorption, though total bioavailability is generally preserved. Urinary alkalinizers (such as sodium bicarbonate, acetazolamide) increase the fraction of mexiletine reabsorbed in the renal tubule by raising urinary pH, potentially increasing plasma levels; urinary acidifiers have the opposite effect.

## Warnings and Precautions

Proarrhythmia Risk and the CAST Legacy

The Cardiac Arrhythmia Suppression Trial permanently altered how Class I antiarrhythmics are prescribed. Although CAST specifically studied flecainide and encainide (both Class IC agents) in post-MI patients with asymptomatic PVCs, the finding that arrhythmia suppression did not translate to improved survival — and actually increased mortality — led to sweeping reevaluation of the entire antiarrhythmic drug class. Mexiletine, as a Class IB agent, is not mechanistically identical to the CAST drugs, but current guidelines nonetheless restrict its use to patients with symptomatic, life-threatening ventricular arrhythmias rather than incidental PVC suppression.

In clinical practice, mexiletine should be initiated in a hospital or closely monitored outpatient setting for new ventricular arrhythmia indications, and a 12-lead ECG should be reviewed before and periodically during therapy to detect conduction abnormalities such as PR prolongation or QRS widening that might signal excessive sodium channel blockade.

Structural Heart Disease

Patients with cardiomyopathy, heart failure, or previous myocardial infarction with reduced left ventricular function are at higher risk of proarrhythmia from mexiletine and other Class I agents. In these patients, the risk-benefit ratio must be carefully weighed, and device therapy (ICD) should generally be in place before initiating mexiletine for ventricular arrhythmia suppression.

Conduction System Disease

Mexiletine is contraindicated in patients with second- or third-degree AV block who do not have a functioning pacemaker. It should be used with extreme caution in patients with significant first-degree block, bundle branch block, or sick sinus syndrome. The drug's sodium channel-blocking properties can slow conduction through an already diseased His-Purkinje system, precipitating high-degree block.

Hepatic Disease

Given mexiletine's extensive hepatic metabolism, liver disease impairs drug clearance and increases the risk of drug accumulation and toxicity. Lower doses, slower titration, and more frequent monitoring of plasma levels and liver function tests are warranted in these patients.

CNS Toxicity

Mexiletine has a relatively narrow therapeutic index with respect to CNS side effects. Tremor and dizziness at therapeutic levels can progress to ataxia, dysarthria, confusion, and seizures at toxic concentrations. Patients should be counseled to report neurological symptoms promptly and to avoid activities requiring fine coordination (driving, operating heavy machinery) until their response to the drug is established.

Pregnancy and Lactation

Mexiletine is classified as FDA Pregnancy Category C. Animal reproduction studies have shown adverse effects on the fetus, and there are no adequate human studies. Mexiletine crosses the placental barrier and has been measured in neonatal serum. It is also excreted in breast milk at concentrations approaching or exceeding maternal plasma levels, posing a theoretical risk to nursing infants. Breastfeeding should generally be avoided during mexiletine therapy; the risk-benefit decision must be individualized.

Narrow Therapeutic Index

The therapeutic range for mexiletine plasma levels is generally cited as 0.5–2.0 mcg/mL. Below this range, arrhythmia control may be inadequate; above this range, CNS side effects become increasingly likely. Plasma level monitoring is particularly valuable when changing other medications that interact with CYP1A2, when hepatic function changes, when the patient starts or stops smoking, or when toxicity is suspected.

## Pharmacokinetics

Understanding mexiletine's pharmacokinetics is important for optimizing dosing and anticipating drug interactions.

Absorption

Mexiletine is well absorbed from the gastrointestinal tract with an oral bioavailability of approximately 87–90% — a marked improvement over lidocaine's near-zero oral bioavailability. Peak plasma concentrations (Cmax) are typically achieved 2–3 hours after oral dosing. The rate but not the extent of absorption is slowed by food or antacids, making these useful strategies to reduce peak-concentration-related GI and CNS side effects.

Distribution

Mexiletine is moderately protein-bound (approximately 50–60% to albumin), with a large volume of distribution (5–7 L/kg), reflecting extensive tissue uptake. The drug distributes into cardiac tissue, skeletal muscle, and the central nervous system.

Metabolism

Mexiletine is extensively metabolized in the liver, primarily by CYP1A2, with lesser contributions from CYP2D6 and CYP3A4. The major metabolites — hydroxymethylmexiletine, p-hydroxymexiletine, and their further oxidized derivatives — are pharmacologically inactive and eliminated in the urine. Because CYP1A2 is the dominant pathway, factors that alter CYP1A2 activity (smoking, drug interactions) have the greatest pharmacokinetic impact.

Approximately 7–10% of individuals of European ancestry are CYP2D6 poor metabolizers. In these individuals, mexiletine metabolism shifts more completely to CYP1A2, modestly increasing exposure, but the clinical effect is generally smaller than would be anticipated for a drug primarily metabolized by CYP2D6.

Elimination

The plasma elimination half-life in healthy adults is approximately 10–12 hours, supporting every-8-hour dosing in most patients. In patients with hepatic cirrhosis or severe heart failure (which reduces hepatic blood flow), the half-life may extend to 15–25 hours, increasing the risk of drug accumulation with standard dosing. Renal clearance of unchanged mexiletine is pH-dependent: in acidic urine, more drug is excreted; in alkaline urine, more is reabsorbed. This means urinary pH-altering agents (diuretics, antacids, sodium bicarbonate, high-dose ascorbic acid) can alter plasma mexiletine levels. Dialysis does not significantly remove mexiletine, owing to its large volume of distribution and protein binding.

Therapeutic Drug Monitoring

Although routine level monitoring is not universally mandated, measuring plasma mexiletine concentrations (target: 0.5–2.0 mcg/mL) is useful when evaluating treatment failure, suspected toxicity, or when drug interactions are anticipated. Samples should be drawn at steady state (after at least 2–3 days of stable dosing) and ideally as a trough level (immediately before the next dose).

## Frequently Asked Questions

1. How long does it take for mexiletine to start working?

For ventricular arrhythmias, many patients notice a reduction in palpitations within the first few days of reaching an effective dose, though it may take 1–2 weeks of dose adjustment to achieve optimal arrhythmia control. For myotonia, the response is often remarkably rapid — many patients with myotonia congenita report significant improvement in muscle stiffness within 2–5 days of starting mexiletine, even at initial doses. For neuropathic pain, a meaningful reduction in pain intensity may take 1–4 weeks. Steady-state plasma concentrations are reached within approximately 2–3 days (approximately 4–5 half-lives).

2. Can I take mexiletine with food?

Yes, and it is strongly recommended. Taking mexiletine with food, milk, or antacids significantly reduces nausea and other gastrointestinal side effects without meaningfully reducing the total amount of drug absorbed. If you experience stomach upset with mexiletine, always try taking it with a meal or snack before concluding that you cannot tolerate the drug.

3. What should I do if I miss a dose?

If you miss a dose and it has been less than 4 hours since the scheduled time, take the missed dose as soon as you remember, then resume your regular schedule. If more than 4 hours have passed, skip the missed dose and take your next dose at the regular time. Do not double up doses. For myotonia patients taking mexiletine once daily (Namuscla), take the missed dose as soon as remembered on the same day; if not remembered until the next day, skip and continue the regular schedule.

4. Is mexiletine safe for the heart? I thought antiarrhythmics could be dangerous.

Mexiletine — like all antiarrhythmic drugs — carries a proarrhythmic risk, meaning it can theoretically worsen or cause new arrhythmias in some patients. This risk is greatest in patients with significant underlying structural heart disease (reduced ejection fraction, prior heart attack, heart failure). The Cardiac Arrhythmia Suppression Trial (CAST) established that suppressing arrhythmias on a monitor does not necessarily improve survival, which is why mexiletine is now reserved for arrhythmias that are truly symptomatic or life-threatening. When used appropriately, with ECG monitoring, in the right patients, mexiletine has a reasonable safety record. Your cardiologist or electrophysiologist will weigh these risks individually.

5. Can mexiletine affect my other medications?

Yes, mexiletine has several important drug interactions. It slows the liver's breakdown of theophylline (used for asthma), which can lead to theophylline toxicity if the dose is not reduced when starting mexiletine. It also inhibits caffeine metabolism. Drugs that inhibit CYP1A2 (such as fluvoxamine, ciprofloxacin) can raise mexiletine levels significantly, while drugs that induce CYP1A2 (rifampin, phenytoin) can lower levels. Always inform your prescriber and pharmacist about all medications, supplements, and herbs you take when starting mexiletine.

6. Does smoking affect mexiletine?

Yes, significantly. Tobacco smoke contains compounds that strongly induce the CYP1A2 liver enzyme responsible for breaking down mexiletine. Smokers metabolize mexiletine approximately 40% faster than non-smokers and typically require higher doses to achieve the same plasma levels. More importantly, if you are a smoker and decide to quit while taking mexiletine, your mexiletine levels may rise substantially over the following weeks as CYP1A2 activity decreases. Alert your prescriber if you change your smoking status so your dose can be monitored and adjusted if needed.

7. Can mexiletine be used during pregnancy?

Mexiletine is classified as Pregnancy Category C, meaning animal studies have shown potential harm to the fetus and there are no adequate human studies. Mexiletine crosses the placenta and has been found in newborn blood. It should only be used during pregnancy if the benefit clearly outweighs the risk — for example, in a pregnant patient with a life-threatening ventricular arrhythmia for which no safer alternative exists. The decision should involve a cardiologist and maternal-fetal medicine specialist. Mexiletine is also present in breast milk and breastfeeding is generally not recommended during therapy.

8. What happens if I take too much mexiletine?

Mexiletine overdose is a medical emergency. At toxic plasma concentrations, the drug produces escalating CNS effects: tremor and dizziness progress to ataxia, confusion, dysarthria (slurred speech), and ultimately seizures. Cardiovascular toxicity includes hypotension, severe bradycardia, conduction block, and potentially fatal ventricular arrhythmias. There is no specific antidote. Treatment is supportive — airway management, benzodiazepines for seizures, vasopressors for hypotension, and atropine or temporary pacing for bradycardia. Dialysis is not effective at removing mexiletine due to its large volume of distribution. If an overdose is suspected, call emergency services immediately.

## Conclusion

Mexiletine occupies a distinctive and enduring niche in clinical pharmacology. As a Class IB antiarrhythmic, it was one of the first oral agents to offer the cardiac sodium channel-blocking properties of lidocaine in a form patients could take at home. Decades of real-world use have refined our understanding of when it helps, when it harms, and how to use it safely.

In the arrhythmia arena, mexiletine is most appropriately used for symptomatic, life-threatening ventricular arrhythmias — not for incidental PVC suppression — a lesson hard-learned from the CAST trial era. It plays a useful role as adjunctive therapy alongside amiodarone in patients with ICD-treated arrhythmias who continue to have unacceptable shock burdens.

In the neuromuscular domain, mexiletine has transformed care for patients with non-dystrophic myotonias. The CINCH trial results and subsequent regulatory approval in Europe established it as the first evidence-based, approved pharmacotherapy for this group of rare but disabling skeletal muscle channelopathies. The drug's ability to reduce muscle stiffness and improve function with reasonable tolerability has made it the standard of care for myotonia congenita and paramyotonia congenita worldwide.

For neuropathic pain, mexiletine remains a second- or third-line option — useful when first-line agents fail or are not tolerated, and particularly in patients where the pain phenotype (burning, lancinating) suggests prominent peripheral sodium channel involvement.

Successful use of mexiletine requires attention to its narrow therapeutic index, its CYP1A2-dominant metabolism, the significant impact of smoking status on drug levels, and its potential to both treat and — in the wrong context — worsen serious cardiac arrhythmias. With careful patient selection, appropriate monitoring, and awareness of key drug interactions, mexiletine remains a clinically valuable and irreplaceable medication for the right patients.

For patients embarking on mexiletine therapy, a few practical principles will help ensure the best outcomes. First, always take the medication with food to minimize nausea and GI upset. Second, be consistent about the dosing schedule — mexiletine's effectiveness depends on maintaining stable plasma levels within the therapeutic window. Third, report any new or worsening symptoms of dizziness, tremor, palpitations, or fainting promptly, as these may signal the need for dose adjustment or additional evaluation. Fourth, inform every healthcare provider — including dentists, who commonly use local anesthetics — that you are taking mexiletine, since the additive sodium channel-blocking effects of combined mexiletine and local anesthetic injections are generally well tolerated but worth noting. Fifth, do not start or stop other medications without checking with your prescriber, given mexiletine's numerous drug interactions through the CYP1A2 pathway.

The future of mexiletine may include expanded roles as our understanding of sodium channelopathies deepens. Ongoing research is exploring its potential in genetic forms of epilepsy caused by sodium channel gain-of-function mutations, in chronic cough conditions linked to airway sensory neuron hypersensitivity, and in certain pain syndromes not yet fully characterized. The drug's long safety record, oral availability, and relatively low cost make it an attractive scaffold for these investigations. Whether via its original cardiac indication, its established neuromuscular applications, or emerging future uses, mexiletine's place in medicine remains secure.